financetom
Business
financetom
/
Business
/
What's Going On With Rocket Lab Stock Wednesday?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Rocket Lab Stock Wednesday?
Jun 4, 2025 6:45 AM

Rocket Lab Corp shares were up about 1% in pre-market trading Wednesday before pulling back slightly with broader markets. Here’s a look at what’s going on.

What Happened: Rocket Lab scheduled its third Electron launch in less than a month after the market close on Tuesday. Shares drifted higher following the announcement.

The mission, called “The Mountain God Guards,” is for a Japan-based Earth imaging company Institute for Q-shu Pioneers of Space. The mission will launch from New Zealand during a launch window that opens on June 10, and place a synthetic aperture radar (SAR) imaging satellite into orbit.

‘The Mountain God Guards’ mission will be the company’s third Electron launch in just 24 days, which Rocket Lab said demonstrates the repeatable, reliable and dedicated access to space the company offers.

The mission represents the company’s eighth Electron launch in 2025 and 66th Electron launch overall.

Check This Out: Apple Has ‘At Least Two Years’ Before Losing Customers Despite Its Several AI Missteps, Says Gene Munster — Here’s Why

Is RKLB A Good Stock To Buy?

Wall Street analysts view Rocket Lab on the whole as a Buy, given the history of coverage over the past three months. Suji Desilva from Roth Capital is the most optimistic, expecting a 40% rise in the stock over the coming year.

Looking at how the market as a whole thinks of the stock, you can reference historical price action for views on whether investors feel strongly about the stock one way or another. In the past three months, Rocket Lab rose 46.09%, which indicates that opinion improved on the business and how attractive it is to own based on either its stock price, or underlying fundamentals, like revenue, which rose 32.13% over the past year.

A complete overview of how Wall Street views individual stocks is available here, while real time updates on the latest analyst actions will be delivered via Benzinga PRO. Try it for free.

RKLB Price Action: Rocket Lab shares were up 0.86% at $26.95 at the time of publication Wednesday, according to Benzinga Pro.

Read Next:

Elon Musk Dismisses Reports That SpaceX Is Valued At $480 Billion, Says It Sounds ‘Too High:’ Predicts Its Revenue Will Exceed NASA’s Budget In 2026

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
DuPont secures 10-year US import ban on China's Dawnsens in Tyvek case
DuPont secures 10-year US import ban on China's Dawnsens in Tyvek case
Sep 8, 2025
Sept 8 (Reuters) - DuPont ( DD ) said on Monday China's Dawnsens New-Materials will not sell or import products tied to the chemical company's Tyvek brand in the U.S. for 10 years, as part of a trade secrets dispute resolution. The International Trade Commission approved Dawnsens', also known as Dangs, voluntary agreement to the consent order. The ban, effective...
Rapport Reports Promising Epilepsy Study Outcomes, Plans Phase 3 Trials Next Year
Rapport Reports Promising Epilepsy Study Outcomes, Plans Phase 3 Trials Next Year
Sep 8, 2025
Rapport Therapeutics, Inc. ( RAPP ) stock traded higher on Monday, with a session volume of 3.20 million compared to the average volume of 179.3 thousand, according to data from Benzinga Pro. On Monday, the company revealed data from the Phase 2a trial of RAP-219 (RAP-219-FOS-201) in patients with drug-resistant focal onset seizures. The study met its primary endpoint, demonstrating...
ImmunityBio Says Anktiva Therapy Prolonged Overall Survival in Phase 2 Non-Small Cell Lung Cancer Study
ImmunityBio Says Anktiva Therapy Prolonged Overall Survival in Phase 2 Non-Small Cell Lung Cancer Study
Sep 8, 2025
09:27 AM EDT, 09/08/2025 (MT Newswires) -- ImmunityBio ( IBRX ) said Monday that results from its phase 2 study showed Anktiva therapy reverses lymphopenia and prolongs overall survival in patients with advanced non-small cell lung cancer. Lymphopenia is an adverse effect associated with chemotherapy, radiotherapy, and immunotherapy, and it lowers overall survival rates in various types of cancer, the...
Bath & Body Works to Hire Over 30,000 Seasonal Workers Ahead of Holidays
Bath & Body Works to Hire Over 30,000 Seasonal Workers Ahead of Holidays
Sep 8, 2025
09:29 AM EDT, 09/08/2025 (MT Newswires) -- Bath & Body Works ( BBWI ) said Monday it plans to hire 30,000 seasonal associates across the US, Canada, and Puerto Rico to meet the expected surge in demand during the holiday season. Roles include part-time seasonal associates to support nearly 1,900 stores and over 2,000 full-time merchandise processors, handlers, outbound loaders...
Copyright 2023-2026 - www.financetom.com All Rights Reserved